Evidence map›Paper›PMID 41739362›Full record

ArticleEJNMMI research2026

Relationship between absorbed dose and SUV derived from SPECT/CT imaging and dose-response in patients with neuroendocrine tumors treated with [¹⁷⁷Lu]Lu-DOTA-TATE.

Fei Liu, Hongxing Yang, Jianping Zhang, Jindian Li, Ying Qiao, Jie Chen, Shaoli Song

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05459844 (A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With Inoperable, Progressive, Well Differentiated, Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine Tumours), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05459844 phase3active not recruitingnot on this map

A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With Inoperable, Progressive, Well Differentiated, Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine Tumours

TypeinterventionalSponsorSinotau Pharmaceutical GroupRan2022 to 2028Enrolled196ConditionsNeuroendocrine TumorsArmsLutetium[177Lu] Oxodotreotide Injection, Octreotide LAR
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Fei Liu *Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China.
Hongxing Yang *Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China.
Jianping ZhangDepartment of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China.
Jindian LiDepartment of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China.
Ying QiaoDepartment of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China.
Jie ChenCenter for Neuroendocrine Tumors, Fudan University Shanghai Cancer Center, Shanghai, China. chen0jie@hotmail.com.
Shaoli SongDepartment of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China. shaoli-song@163.com.ORCID http://orcid.org/0000-0003-2544-7522

Funding

Major Program of National Natural Science Foundation of China U23A20465Shanghai Pujiang Program 22PJ1401700Shanghai Science and Technology Commission Project 23DZ2291400Shanghai Science and Technology Commission Project 23TS1400800
6 · The paper itself

Abstract

backgroundThe aim of this study was to evaluate the efficacy of neuroendocrine neoplasms (NENs) patients treated with peptide receptor radionuclide therapy (PRRT), and to investigate the relationships among the absorbed dose of the tumor target lesions, standardized uptake value (SUV), and the therapeutic efficacy of the patients. A total of 22 NENs patients who received [

resultsAfter the patients received [

conclusionsThrough the calculation and analysis of the radionuclide therapy dosimetry based on the SPECT/CT images throughout the PRRT treatment of the patients, the absorbed dose and SUV of the patients can provide important dose guidance for radionuclide therapy, which is helpful to improve the treatment efficacy of the patients.

trial registrationA Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs, NCT05459844. Registered 5 July 2022, https://clinicaltrials.gov/study/NCT05459844?cond=NCT05459844&rank=1 .

Indexed as

[177Lu]Lu-DOTA-TATEAbsorbed doseDose-responseSPECT/CTSUV

Identifiers

PMID41739362
PMCPMC13038717

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.